Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Daniel Fischer, president and CEO of Tevard Biosciences. Fischer and his business partner, Warren Lammert are both fathers of girls with Dravet syndrome, and Tevard is “Dravet” spelled backward. The company is developing technologies to modulate RNA function to treat rare and severe diseases such as Dravet syndrome that are usually not amenable to traditional gene therapy.
Read the full story: Tevard Biosciences Pursues Gene Therapy to Treat Dravet Syndrome, and Possibly DMD
